The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy.
Michael V MartinSalvador Aguilar-RosasKatka FrankeMark PieterseJamie van LangelaarRenee Rce SchreursMaarten F BijlsmaMarc G H BesselinkJan KosterHidde J HaismaMustafa KhasrawDavid M AshleyStephen T KeirChristian Hermann OttensmeierEmma V KingJoanne VerheijCynthia WaasdorpPeter J M ValkSem A G EngelsEllen OostenbachJip T van DinterDamon A HofmanJuk Yee MokWim J E van EschHanneke WilminkKim MonkhorstHenk M W VerheulDennis PoelThijo Jeroen N HiltermannLéon C L T van KempenHarry J M GroenJoachim G J V AertsSebastiaan van HeeschBob LöwenbergRonald PlasterkWigard P KloostermanPublished in: Cancer immunology research (2024)
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate cancer whole genome and long-read transcript sequencing to identify the collection of novel open reading frame peptides (NOPs) expressed in tumors, termed the framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe an uncharacterized class of hidden NOPs, which derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of non-coding regions of the genome downstream of a rearrangement breakpoint. NOPs represent a vast amount of possible neoantigens particularly in tumors with many (complex) structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T-cells specific for hidden NOPs in lung cancer patient peripheral blood.